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There is compelling evidence that preconditioning occurs in humans. Experimental studies with
potential clinical implications as well as clinical studies evaluating ischaemic, pharmacological
and anaesthetic cardiac preconditioning in the perioperative setting are reviewed. These
studies reveal promising results. However, there are con¯icting reports on the ef®cacy of pre-
conditioning in the diseased and aged myocardium. In addition, many anaesthetics and a signi®-
cant number of perioperatively administered drugs affect the activity of cardiac sarcolemmal
and mitochondrial KATP channels, the end-effectors of cardiac preconditioning, and thereby
markedly modulate preconditioning effects in myocardial tissue. Although these modulatory
effects on KATP channels have been investigated almost exclusively in laboratory investigations,
they may have potential implications in clinical medicine. Important questions regarding the
clinical utility and applicability of perioperative cardiac preconditioning remain unresolved and
need more experimental work and randomized controlled clinical trials.
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Brief episodes of sublethal cardiac ischaemia protect against
subsequent prolonged ischaemia. The phenomenon is
termed `preconditioning' and represents an endogenous
protective mechanism inherent to all tissues with high-
energy consumption. Preconditioning has been described in
the kidney,95 liver,73 small intestine,67 lung52 and brain.27 It
is tempting to speculate that this protective adaptive
mechanism developed during the evolutionary process to
increase cell survival within specialized tissues in response
to temporal shortages of nutrient supply and repetitive
noxious stimuli.
Part I of this review108 focused on the important
signalling steps and the cytoprotective mechanisms under-
lying ischaemic, pharmacological and anaesthetic-induced
preconditioning in cardiac tissue. Particularly, it noted that
volatile anaesthetics and opioids induce cardiac precon-
ditioning. The signalling cascades involve alterations in
nitric oxide and free oxygen radical formation and several
G-protein-coupled receptors (adenosine and a/b-adrenergic
receptors), and point to the key role of protein kinase C
(PKC) as a signal ampli®er and to the KATP channels as the
main end-effectors in preconditioning. Laboratory investi-
gations also stress the concept that anaesthetics may
precondition endothelial and smooth muscle cells, the
main components of blood vessels.17 As blood vessels are
responsible for the supply of nutrients and oxygen to all
tissues, anaesthetic preconditioning might bene®cially
affect a much wider variety of organs, including the brain,
spinal cord, liver and kidneys.
Part II of this review discusses experimental studies with
clinical implications, and the clinical studies that provide
evidence for perioperative cardiac preconditioning, particu-
larly anaesthetic-induced preconditioning. In addition, the
modulatory effects of anaesthetics and perioperative medi-
cation and the in¯uence of disease states on cardiac
preconditioning are reviewed.
Evidence of preconditioning in humans
Coronary angioplasty, unstable and `warm-up'
angina
The myocardial adaptation observed in patients undergoing
percutaneous transluminal coronary angioplasty (PTCA)
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strongly suggests that preconditioning also occurs in
humans.18 Most, but not all,19 studies have demonstrated
increased tolerance to ischaemia with repeated balloon
in¯ations. A single 90-s balloon occlusion immediately
before angioplasty markedly decreased periprocedural
release of phosphocreatine kinase.45 Unstable angina
occurring in the 24 h before infarction can precondition
the heart,68 and preinfarct angina led to improved long-term
survival compared with patients who were asymptomatic
before the ischaemic insult.42 Both observations may re¯ect
classic or delayed preconditioning. Recently, Leesar and
colleagues50 found that nitroglycerin infusion 24 h before
PTCA with three 2-min balloon in¯ations interspersed with
5 min of reperfusion markedly enhanced tolerance of
ischaemia, using ST-segment changes, ischaemic dysfunc-
tion and chest pain as the study end-points. This is the ®rst
study which provides evidence that delayed preconditioning
also occurs in humans. It also showed that collateral vessel
recruitment is not involved in the observed improvement
and that early preconditioning effects, as assessed by ST-
segment changes, occur after only two 2-min episodes of
ischaemia. Another clinical correlate of preconditioning is
so-called warm-up angina, a phenomenon which describes
relief of anginal pain in response to increased duration of
exercise.65 Consistent with an early and delayed window of
protection, patients with stable angina exhibit less stunning
after exercise-induced myocardial ischaemia, or if a
preceding exercise was performed, they had improved
exercise tolerance 24 h after the exercise.15
Ischaemic preconditioning in coronary artery bypass
surgery
On-pump procedures
Patients undergoing coronary artery bypass graft (CABG)
surgery are an ideal model for studying the effects of
preconditioning. Intermittent ischaemia achieved by aortic
cross-clamping in a ®brillating heart during CABG surgery
was used by Jenkins and colleagues34 to evaluate the
ischaemic preconditioning effect. Two cycles of 3-min
ischaemic episodes (induced by intermittent aortic cross-
clamping and pacing the heart at 90 beats min±1), each
followed by 2 min of reperfusion before a prolonged
ischaemia of 10 min (induced by aortic cross-clamping), led
to increased ATP preservation and decreased troponin T
release compared with untreated patients. A 1-min episode
of aortic cross-clamping before cold-blood cardioplegia
followed by 5 min of reperfusion signi®cantly improved
heart function 1 h after surgery in another study, and
decreased the need for inotropic support in patients
undergoing open-heart surgery.30 Similarly, improved car-
diac function, and decreased release of phosphocreatine
kinase MB isoenzyme was shown in patients undergoing
valve replacement when receiving two cycles of 3 min of
aortic cross-clamping, each followed by 2 min of
reperfusion before cardioplegic arrest.56 However, one
trial with patients undergoing CABG surgery using one
3-min episode of aortic cross-clamping before the onset of
warm-blood cardioplegic arrest failed to show bene®cial
effects, but rather exhibited exacerbated ischaemic
damage.74 Increased phosphocreatine kinase release and
lactate production were observed in these patients. It is
assumed that protective effects of preconditioning during
CABG surgery may only become demonstrable if cardio-
plegic protection is inadequate8 or ischaemic times are
long.12 In addition, differences in surgical techniques
(normothermic vs hypothermic, ®brillation vs cardioplegic
arrest) and study end-points (haemodynamic vs metabolic vs
cardiac enzymes vs clinical outcome variables) make a
direct comparison between these studies impossible.
Off-pump procedures
In off-pump, beating-heart CABG surgery, temporary
segmental occlusion of coronary arteries is required for
successful suturing of the anastomosis. Ischaemic pre-
conditioning may be used to preserve cardiac function
during this critical time. Jacobson and colleagues33 reported
favourable effects of ischaemic preconditioning on
pressure-area loops, as assessed by transoesophageal
echocardiography, in patients undergoing minimally inva-
sive CABG. A recent study in patients undergoing off-pump
CABG surgery46 investigated whether ischaemic precondi-
tioning by occluding the left anterior descending coronary
artery before bypass grafting would enhance myocardial
performance. Decreased myocardial enzyme release and
increased myocardial function was observed in precondi-
tioned patients. Conversely, Malkowski and colleagues58
did not observe functional improvement by ischaemic
preconditioning during minimally invasive CABG surgery.
Vigorous surgical manipulations and pharmacological
stimulation by catecholamines with the potential to induce
preconditioning may overwhelm any bene®t from thera-
peutic ischaemia.57
Volatile anaesthetic-induced preconditioning in
CABG surgery
Volatile anaesthetics are well suited to preconditioning
during the operative period as they can be administered via
the ventilator or the cardiopulmonary bypass oxygenator.
Only a few, small studies have investigated the precondi-
tioning effects of volatile anaesthetics in human myocar-
dium (Table 1). So far, three studies have evaluated the
preconditioning effects of iso¯urane3 25 93 and one the
effects of en¯urane72 on either post-ischaemic cardiac
dysfunction or the release of cardiac injury markers in
patients undergoing CABG surgery under cardioplegic
arrest. A small study compared sevo¯urane with propofol
anaesthesia in CABG patients and found improved post-
operative myocardial function in the sevo¯urane patients.16
This study of only 20 patients further claimed that
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sevo¯urane would decrease the release of cardiac troponin I,
which is surprising considering the marked variability
between patients and the large number of surgical
techniques.16 Nonetheless, pharmacological induction of
preconditioning, in contrast to classic ischaemic precondi-
tioning, would be desirable, speci®cally in high-risk patients
such as CABG surgery patients, in whom an ischaemic-type
of preconditioning may further jeopardize diseased myo-
cardium. Tomai and colleagues93 gave iso¯urane for 15 min
at 1.5 vol/vol % through the ventilator followed by a
washout period of 10 min before starting cardiopulmonary
bypass. No differences in haemodynamic variables, such as
cardiac index and left ventricular ejection fraction, were
found between control and preconditioned groups.
However, a decrease in postoperative phosphocreatine
kinase MB and troponin I release could be detected in
patients with a poor preoperative left ventricular ejection
fraction (<50%) (Table 1). Conversely, when administering
iso¯urane 0.5±2 vol/vol % shortly before cardiopulmonary
bypass through the ventilator, Haroun-Bizri and col-
leagues25 demonstrated improved haemodynamic recovery
and decreased ST-segment changes, but no reduction in
dysrhythmias in the immediate reperfusion period.
Administration of iso¯urane 2.7 vol/vol % for 5 min on
established cardiopulmonary bypass followed by a 10-min
washout period before aortic cross-clamping only showed a
tendency to lower phosphocreatine kinase MB isoenzyme
and troponin I release (not statistically signi®cant).3 Penta
de Peppo and colleagues72 applied en¯urane 1.3 vol/vol %
over 5 min immediately before cardiopulmonary bypass.
Preconditioning afforded increased left ventricular contrac-
tility, but no decrease in perioperative phosphocreatine
kinase MB isoenzyme or cardiac troponin T release was
noted. As raised concentrations of myocardial enzymes after
CABG surgery can occur from cannulation of the right
atrium, cardioplegia, inadequate delivery of cardioplegia
in the presence of stenosis or hypertrophy, vigorous
manipulations of the heart, prolonged surgery and
differences in surgical techniques, they may not properly
re¯ect the protection afforded by preconditioning.
Collectively, these data provide some evidence that volatile
anaesthetics may protect human hearts by anaesthetic
preconditioning.
Preconditioning signal transduction pathways in
human myocardium
Experimental studies on human tissue and clinical studies
with patients support the concept that the signalling
pathways that mediate preconditioning in humans are the
same as those observed in animal models. The signalling
steps and the cytoprotective mechanisms of ischaemic and
anaesthetic preconditioning were described in detail in Part
I of this review.108
Human cardiomyocytes and myocardial tissue
The involvement of a1-adrenergic receptors, bradykinin B2
receptors, adenosine 1, PKC and KATP channels (including
mitochondrial channels) in human cardiomyocytes and
myocardial tissue has been demonstrated.11 13 Cytosol-to-
membrane translocation in response to adenosine stimula-
tion was previously shown for the a isoform of PKC in
human cardiomyocytes.29 Many of these signalling
components, including adenosine receptors, adrenergic
receptors and the sarcolemmal and mitochondrial KATP
channels, were also demonstrated to be related to the
preconditioning elicited by volatile anaesthetics in human
tissue.24 78
Clinical studies
Adenosine antagonists such as aminophylline and bami-
phylline can prevent adaptation to ischaemia during
repeated balloon in¯ation,90 and intracoronary adenosine
and bradykinin administration was as effective as ischaemic
preconditioning.49 51 Also, adaptation to ischaemia can be
induced by morphine and abrogated by naloxone92 or
phentolamine,91 suggesting that opioid and a-adrenergic
receptors play an important role in human myocardium.
Involvement of PKC and KATP channels was shown in some
clinical studies. Ecto-5¢-nucleotidase, a marker of PKC
activity, was increased in response to iso¯urane adminis-
tration in patients undergoing CABG surgery.3 Nicorandil, a
mitochondrial KATP channel opener, reduces ST-segment
changes in patients undergoing PTCA, and perioperatively
in patients undergoing abdominal surgery.36 Clinically used
oral sulfonylurea agents, used to treat type II diabetes
mellitus and potent blockers of the KATP channels,
effectively abolish cardiac preconditioning.41
Modulatory effects of anaesthetics and
perioperative medication on cardiac
preconditioning
Anaesthetics
Many anaesthetics have profound effects on sarcolemmal
and mitochondrial membranes, the putative sites of the end-
effectors for preconditioning, at concentrations as low as
those known to produce general anaesthesia. It is therefore
not surprising that cardiac preconditioning can be prevented
by different anaesthetics. Anaesthetics with mostly inhibi-
tory or no effects on KATP channels are listed in Table 2.
Inhibition of this important endogenous protective mech-
anism may be a hazard. To date, there are only sparse
clinical data addressing this important topic.100 In rabbit
hearts, racemic ketamine, but not the stereoisomer S-
ketamine, was found to block early and late
preconditioning.63 64 Racemic ketamine and the stereo-
isomer of ketamine were also shown to block both types
of KATP channel in isolated rat cardiomyocytes.
43 107
Similarly, the barbiturate thiamylal,99 which closely
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resembles thiopental in its chemical structure, inhibits
sarcolemmal KATP channels. Two laboratories independ-
ently showed that commonly used barbiturates inhibit
mitochondrial KATP channel activity.
44 107 No inhibitory
effects on mitochondrial KATP channels were found for
xylazine, an a2-adrenergic agonist similar to clonidine,
dexmedetomidine and mivazerol.108 Similarly, propofol,
etomidate and midazolam did not have any effect on KATP
channels or ischaemic myocyte survival in a rat model.37 107
Taken together, these studies support the concept that
certain anaesthetics may antagonize the protective effects of
preconditioning.
Perioperative medication
Frequently used drugs that may inhibit or enhance
ischaemic preconditioning are listed in Table 3.
Sulfonylurea hypoglycaemic agents prevent ischaemic
preconditioning13 and are thought to be responsible, in
part, for the reported increase in cardiovascular mortality in
patients treated with these agents.20 61 However, this has
been questioned recently.22 Importantly, recent observa-
tions in type-2 diabetes patients suggest that glibenclamide-
induced inhibition of preconditioning-related cardioprotec-
tion can be prevented by changing the antidiabetic treatment
to insulin.82 Because b-blockers are thought to have
bene®cial perioperative effects109 110 and to reduce early76
and late60 perioperative cardiovascular morbidity and
mortality, the suggested inhibitory effects of b-blockers
on cardiac preconditioning (Table 3) appear somewhat
con¯icting, with their strong perioperative cardioprotection.
However, metoprolol, a pure b-blocking agent, did not
neutralize the favourable effects of preconditioning in
pigs.103 In addition, b-adrenergic receptors represent only
one signalling pathway by which preconditioning can be
triggered, and speci®c alterations in the diseased heart, such
as downregulation of G-protein-coupled receptors, may
diminish the protective effects of preconditioning.
Effects of preconditioning in the aged and
diseased heart
Most experimental studies have evaluated the phenomenon
of preconditioning in healthy juvenile hearts. This approach
is far from clinical reality, as diseased myocardium would
bene®t most from this protection. Some clinical and
experimental studies provide evidence that diseased myo-
cardium may be less amenable to the protective effects of
preconditioning (Table 4).
Ageing
Preconditioning protection may be lost in aged myocar-
dium. Even worse, increased deleterious effects of ischae-
mia were reported in preconditioned aged rat hearts.88 This
effect appears to be due to the insuf®cient translocation of
PKC isoforms in response to the preconditioning stimulus.87
These experimental ®ndings are supported by two clinical
studies in which the anti-arrhythmic and infarct-limiting
effects of prodromal angina were lost in elderly patients
with myocardial infarction.1 32 In contrast, JimeÂnez-Navarro
and colleagues35 found that the occurrence of angina 1 week
before myocardial infarction still conferred protection
against in-hospital adverse outcomes in patients aged
>70 yr. However, a more recent clinical study in patients
undergoing PTCA, comparing ischaemic preconditioning in
younger (45 (SD 5) yr) and elderly patients (71 (3) yr), also
suggests that ischaemic preconditioning is attenuated in the
aged human myocardium, most probably as a result of age-
related inhibitory effects upstream of the mitochondrial
KATP channels.
48
Metabolic dysfunction: hypercholesterolemia and
diabetes
Rabbit myocardium loses its preconditioning-induced pro-
tection when exposed to a cholesterol-enriched diet for more
than 4 weeks,85 and markedly increased serum glucose
concentrations (>500 mg dl±1) can inhibit KATP channel
Table 2 Intravenous anaesthetics with inhibitory effects or no effects on mitochondrial and sarcolemmal KATP channels. ¬®=no effect; ­=increased effect;
¯=decreased effect. #Only at high concentrations
Anaesthetic drug Mitochondrial KATP
channel activity
References Sarcolemmal KATP
channel activity
References
R-ketamine ¯ 63, 64, 107 ¯ 43, 63, 64
S-ketamine ¬® 107 ?
Propofol ¬® (¯#) 37, 44, 107 ¬® (¯#) 37
Etomidate ¬® 107 ?
Thiopental ¯ 107 ?
Midazolam ¬® 107 ?
Pentobarbital (used in the laboratory) ¯ 44, 107 ¯ 23
Thiamylal (used in the laboratory) ? ¯ 100
Xylazine (used in the laboratory) ¬® 107 ?
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activation per se.38 Tosaki and colleagues96 reported a loss
of protection by preconditioning in streptozotocin-induced
diabetic rat hearts. Conversely, Liu and colleagues54
demonstrated that preconditioning reduces infarct size in
non-insulin-dependent diabetic rats to the same extent as in
normal hearts. One study found less pronounced release of
cardiac enzymes in preconditioned isolated perfused hearts
of streptozotocin-treated diabetic rats compared with
preconditioned hearts of normal rats.89 More recently,
iso¯urane-induced preconditioning was found to be attenu-
ated in diabetic dogs.86 Some of these experimental results
are consistent with clinical observations in which prodromal
angina did not limit infarct size, enhance recovery of
myocardial function or improve survival in diabetic patients
with myocardial infarction, as opposed to non-diabetic
patients.31
Remodelled heart
The effects of preconditioning have been shown to be
operative in three rat models of hypertrophied myocardium
(deoxycorticosteroid-treated and salt-fed rats,83 spon-
Table 3 Modulatory effects of medication on cardiac preconditioning. NSAIDs=non-steroidal anti-in¯ammatory drugs; COX-2=cyclooxygenase 2
Preconditioning ­ Preconditioning ¯
Adenosine receptor agonists49 Adenosine receptor antagonists90
Including nucleotide transporter inhibitors (acadesine,7 59 dipyridamol70) Theophylline, aminophylline
KATP channel openers KATP channel blockers
(Nicorandil,71 diazoxide, cromakalim, levosimendan,39 minoxidil,
benzocaine, p-diethylaminoethylbenzoate), including the uncoupler of
oxidative phosphorylation: bupivacaine, ropivacaine, most NSAIDs84
Sulfonylurea agents, including antidiabetic drugs: glibenclamide, glyburide.
Much less: glimepiride,41 and anticancer drugs (diarylsulfonylurea),84
lidocaine, mexiletine98
Opioid agonists (probably via d1) Opioid antagonists
Morphine,80 pentazocine, fentanyl Naloxone92
b-Adrenergic receptor agonists104 b-Adrenergic receptor antagonists55
Isoproterenol, norepinephrine, epinephrine. Some b-blockers with
auxiliary effects may enhance preconditioning,109 such as carvedilol,66
nipradilol28 and nebivolol
Including drugs which deplete myocardial tissue of catecholamines, such
as reserpine94
a1-Adrenergic receptor agonists102 a1-Adrenergic receptor antagonists
Phenylephrine, norepinephrine Phentolamine
M2-muscarinic receptor agonists
5 M2-muscarinic receptor antagonists
Acetylcholine esterase inhibitors Atropine
Nitric oxide releasers Nitric oxide scavengers
Nitroglycerin,50 nitroprusside, L-arginine Vitamin E?
Ca2+ 62 Ca2+ channel blocker
Nifedipine101
B2-bradykinin receptor agonists
51 81
Angiotensin converting enzyme inhibitors: captopril, lisinopril, enalapril
AT1-receptor antagonists
9
Statins
Lovastatin, pravastatin, via activation of ecto-5¢-nucleotidase47
Flumazenil106
Amrinone79
Digoxin26
Gadolinium75
Aprotinin6
COX-2 inhibitors4
Table 4 Factors affecting the ef®cacy of cardiac preconditioning. ¬®=no effect; ­=increased effect; ¯=decreased effect
Factors/disease states Ischaemic
preconditioning
References Anaesthetic
preconditioning
References
Diabetes ¯/¬®/­ 31, 38, 54, 96 ¯ 86
Medication ¯/¬®/­ (Table 3 in present paper) ¯/¬®/­ (Table 3 in present paper)
Increased age ¯/¬® 1, 32, 35, 48, 87, 88 ?
Raised plasma cholesterol ¯ 85 ?
Coronary artery disease (ischaemic cardiac remodelling) ¯/¬® 48, 53 ?
Arterial hypertension (hypertrophic cardiac remodelling) ¯/¬® 5, 69, 77, 83 ?
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taneously hypertensive rats5 and transgenic hypertensive
rats77). Conversely, in a dog model of hypertrophy (aortic
stenosis), there was no evidence of cardioprotection with
preconditioning.69 Results from muscle slices of human
right atrial appendages of patients with a left ventricular
ejection fraction <30% indicate that failing human myo-
cardium is much less amenable to ischaemic precondition-
ing.21 In contrast, successful preconditioning can be
established in severely atherosclerotic knockout mice
(ApoE/LDLr±/±).53
Questions and perspectives
Preconditioning by anaesthetics represents a promising new
therapeutic strategy in patients undergoing PTCA, CABG
surgery (including off-pump procedures) or valve replace-
ment, and in the preservation of donor hearts.40
Pharmacological preconditioning may even exert better
protection than ischaemic preconditioning.97 However, in
short surgical procedures with optimal cardioplegic protec-
tion or short ischaemic periods, loss of function and cell
death may be negligible. Furthermore, it remains to be
established whether diseased and aged myocardium can be
preconditioned in the same manner as healthy myocardium.
Although it is possible to re-initiate preconditioning once it
has worn off,105 there is currently sparse experimental
evidence indicating that cardiac tissue can be constantly
maintained in a protective preconditioned state. Dana and
colleagues14 showed in a rabbit model that repeated
administration of an adenosine receptor agonist, with a
48-h interval schedule, can maintain the heart in a protective
state against myocardial infarction with no evidence of
tachyphylaxis. However, continuous stimulation of the
preconditioning mechanism may lead to tachyphylaxis. In
this regard, late preconditioning may be more attractive,
though less effective. Late preconditioning has been
demonstrated for opioids, but not for volatile anaesthetics.
Moreover, silent ischaemia, overt angina or warm-up angina
may already precondition high-risk cardiac patients and
thereby abrogate the bene®cial effects of pharmacological
interventions. Recently, Aitchison and colleagues2 pre-
sented experimental evidence that there may exist an `anti-
preconditioned' state of the myocardium. By means of
pre-ischaemic transient k1-opioid receptor stimulation in
isolated perfused rat hearts, a sizeable increase in infarct
size compared with ischaemia alone was achieved. This
observation implies that transient receptor stimulation may
make the heart more vulnerable to necrosis (`death memory'
vs `survival memory' by preconditioning). The discovery of
pro-injurious anti-preconditioning effects opens up a fas-
cinating ®eld for future studies in experimental and clinical
cardioprotection. Some of the commonly used perioperative
medications may induce anti-preconditioning in cardiac
tissue and thereby affect outcome. Prophylactic treatment
with pharmacological preconditioning should be used with
extreme care. The combination of ischaemic precondition-
ing and antecedent prophylactic treatment with nicorandil
can abolish the protection afforded by ischaemia in human
trabeculae,10 and halothane can inhibit the effects of
hypoxic preconditioning.78 No direct extrapolation should
be made from theoretical experimental knowledge, and the
effects of each preconditioning protocol need to be evalu-
ated in randomized controlled trials.
Conclusions
Cardiac preconditioning is an area of basic research with
clinical relevance. Human myocardium is amenable to this
form of protection. Although the key signalling steps and
ultimate cellular protective mechanisms underlying cardiac
preconditioning have been unravelled, many questions
remain unresolved, particularly with respect to the aged
and diseased myocardium. The concept that many anaes-
thetics interact with the endogenous cardioprotection
elicited by preconditioning should be considered carefully
in experimental and clinical medicine. Although there is
some promising evidence that anaesthetic preconditioning
may improve the perioperative cardiovascular outcome in
patients at high risk of cardiovascular complications, its
de®nitive role in clinical practice needs to be established in
randomized controlled clinical trials.
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Addendum
Anaesthetic-induced preconditioning in humans
During the review process of this article, a double-blinded,
placebo-controlled study on the protective effect of
sevo¯urane preconditioning in 72 patients undergoing
CABG surgery was published by Julier and colleagues.111
Sevo¯urane preconditioning signi®cantly decreased post-
operative release of NT-proBNP (N-terminal pro-brain
natriuretic peptide), a sensitive biochemical marker of
myocardial contractile dysfunction. Pronounced PKC d and
e translocation was observed in sevo¯urane-preconditioned
myocardium. In addition, the postoperative cystatin C
plasma concentration (a more sensitive marker of subtle
changes in renal glomerular ®ltration rate than plasma
creatinine) increased signi®cantly less in sevo¯urane-
preconditioned patients. No differences between groups
(sevo¯urane vs placebo) were found for perioperative
ST-segment changes, arrhythmias or phosphocreatine
kinase-MB and cardiac troponin T release. In summary,
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sevo¯urane preconditioning preserves myocardial and renal
function, as assessed by biochemical markers in patients
undergoing CABG surgery. This suggests that anaesthetic
preconditioning may elicit more global protection. In
contrast, Pouzet and colleagues,112 assessing the activation
of PKC, p38 mitogen-activated protein kinase and tyrosine
kinase in atrial biopsies of 20 sevo¯urane-preconditioned
patients undergoing CABG surgery, did not observe
signi®cant differences in enzyme activities compared with
control patients. However, all kinases were signi®cantly
activated, probably as a result of the stimulus by the
cardiopulmonary bypass. No decrease in cardiac troponin I
release was reported in patients preconditioned with
sevo¯urane.
Preconditioning-inducing drugs
Lee and colleagues113 demonstrated that administration of
oestrogen in women undergoing coronary angioplasty
diminishes signs of myocardial ischaemia, as assessed by
ECG. Another study showed infarct size-limiting effects by
sildena®l (Viagra) mediated by mitochondrial KATP
channels in a rabbit model of regional ischaemia.114
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